Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547863 | 0.80 | PNMT (0.62) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL1145808 | 0.79 | — | — | |
| SCHEMBL3302008 | 0.79 | PNMT (0.68) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL1043017 | 0.78 | PNMT (0.60) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL27760452 | 0.77 | PNMT (0.65) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL42705 | 0.77 | PNMT (1.00) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL283449 | 0.77 | PNMT (0.65) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL12457076 | 0.75 | PNMT (0.62) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL111152 | 0.75 | PNMT (0.62) | PNMTTAAR1IDO1KDM4EALDH1A1 | |
| SCHEMBL21814337 | 0.75 | PNMT (0.62) | PNMTTAAR1IDO1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4690923-A | ANTITHROMBOTICS | KARL THOMAE GMBH (DE) | 1987-09-01 | — | — | US | claimed |
| US-4518596-A | Antithrombotic use of 2-(perhydro-1,4-diazino)-pyrimido (5,4,D)-pyrimidines | DR. KARL THOMAE GMBH (DE) | 1985-05-21 | — | — | US | claimed |
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6033909-A | INHIBITORS OF GENE EXPRESSION | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-03-07 | — | — | US | disclosed |
| US-5773437-A | UROGENITAL DISORDERS SUCH AS DYSURIA | NIPPON CHEMIPHAR CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0753514-A1 | ALKYLENEDIAMINE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5218088-A | Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates | PURDUE RESEARCH FOUNDATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-4478833-A | ANTICOAGULANTS | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | PNMT 2392/4885TAAR1 4002/4885IDO1 4247/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | PNMT 4186/4885TAAR1 1266/4885IDO1 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.